Psyence Biomedical Ltd
PBMWW0.011USD
-0.004-28.38%
Close 04/24, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Psyence Biomedical Ltd Company
Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The Company has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.
Company Info
Company codePBMWW
Company namePsyence Biomedical Ltd
IPO dateDec 10, 2021
Founded at2023
CEODr. Neil Maresky
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address121 Richmond Street West Penthouse
CityTORONTO
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeM5H 2K1
Phone17744604171
Website
Company codePBMWW
IPO dateDec 10, 2021
Founded at2023
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Neil Maresky
Dr. Neil Maresky
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Warwick Corden-Lloyd
Mr. Warwick Corden-Lloyd
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Marc Balkin
Mr. Marc Balkin
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Bull
Mr. Christopher (Chris) Bull
Independent Director
Independent Director
--
--
Dr. Seth Feuerstein
Dr. Seth Feuerstein
Independent Director
Independent Director
--
--
Dr. Jody Aufrichtig
Dr. Jody Aufrichtig
Chairman of the Board, Strategic Business Development Officer
Chairman of the Board, Strategic Business Development Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Neil Maresky
Dr. Neil Maresky
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Warwick Corden-Lloyd
Mr. Warwick Corden-Lloyd
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Marc Balkin
Mr. Marc Balkin
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Bull
Mr. Christopher (Chris) Bull
Independent Director
Independent Director
--
--
Dr. Seth Feuerstein
Dr. Seth Feuerstein
Independent Director
Independent Director
--
--
Dr. Jody Aufrichtig
Dr. Jody Aufrichtig
Chairman of the Board, Strategic Business Development Officer
Chairman of the Board, Strategic Business Development Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Mon, Mar 10
Update time: Mon, Mar 10
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Other
100.00%
Shareholder Statistics
Shareholder
Proportion
Other
100.00%
Type
Shareholder
Proportion
Other
100.00%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
54
5.78M
0.00%
-3.46M
2024Q4
58
4.63M
0.00%
-5.55M
2024Q3
65
6.46M
0.00%
-4.73M
2024Q2
67
6.76M
0.00%
-3.47M
2024Q1
67
6.93M
0.00%
-3.84M
2023Q4
66
8.24M
0.00%
-2.37M
2023Q3
64
8.66M
0.00%
-1.45M
2023Q2
63
8.16M
0.00%
-2.52M
2023Q1
62
8.81M
0.00%
-1.80M
2022Q4
58
9.69M
0.00%
+104.01K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Harraden Circle Investments, LLC
1.15M
0%
+1.15M
--
Dec 31, 2024
Polar Asset Management Partners Inc.
733.00K
0%
--
--
Dec 31, 2024
MMCAP Asset Management
600.00K
0%
--
--
Dec 31, 2024
Calamos Advisors LLC
500.00K
0%
--
--
Dec 31, 2024
Cantor Fitzgerald, L.P
468.50K
0%
--
--
Dec 31, 2024
Saba Capital Management, L.P.
297.85K
0%
--
--
Dec 31, 2024
Aristeia Capital, L.L.C.
272.86K
0%
--
--
Dec 31, 2024
Goldman Sachs & Company, Inc.
200.12K
0%
--
--
Dec 31, 2024
LMR Partners LLP
200.00K
0%
+200.00K
--
Dec 31, 2024
Periscope Capital
200.00K
0%
-25.00K
-11.11%
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data